Lung Disease Therapeutics Market Size, Share and Trends 2026 to 2035

What is the Lung Disease Therapeutics Market Size?

The global lung disease therapeutics market size is expected to be valued at USD 96.82 billion in 2025 and is anticipated to reach around USD 173.48 billion by 2035, expanding at a CAGR of 6.01% over the forecast period 2026 to 2035.

Lung Disease Therapeutics Market Key Takeaways

• North America led the global market with the highest market share of 36% in 2025.
• By disease type, the Asthma segment residential the biggest market share in 2025.
• By drug class, the corticosteroids segment has held the highest market share in 2025.
• By molecule type, the biologics segment registered the maximum market share in 2025.
• By distribution channel, the hospitals segment held a dominant presence in the lung disease therapeutics market in 2025.

What are Lung Disease Therapeutics?

The lung disease therapeutics market refers to the drugs and cures involved in treating lung disorders. Symptoms include shortness of breath, cough, and chest pain. According to the National Heart, Lung, and Blood Institute, May is considered "National Asthma and Allergy Awareness Month." According to the Centers for Disease Control and Prevention external link, the United States has asthma of about 1 in 13 people, which affects people of every age group and often starts in childhood. It occurs due to external factors such as pollen grains, viral infections, cold air, or exercise.

How is AI contributing to the Lung Disease Therapeutics Industry?

Artificial intelligence is well-known for its ability to improve the therapeutic approach for lung diseases by conducting a thorough analysis of clinical, imaging, and genomic data to provide support in the diagnosis process, the personalization of the treatment, the prediction of disease progression, and the monitoring of adherence. It also facilitates drug discovery, increases the accuracy of diagnosis, helps in the making of care decisions that are proactive, and allows continuous patient monitoring through digital health tools and intelligent clinical decision support systems.

Lung Disease Therapeutics Market Growth Factors

The global lung disease therapeutics market is projected to grow significantly due to active research and development on lung disease. In lung diseases, it promotes the regeneration of damaged lung tissue and improves lung function. Few growth factors (proteins) such as insulin-like growth factor (IGF), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and fibroblast growth factor (FGF) are studied under various lung diseases, including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (IPF).

The therapeutics market for lung disease is still in its early phase, with most drugs still in the preclinical or early clinical stages. Furthermore, a few therapeutics are prospered for lung diseases, including biologics and small-molecule drugs. The market for lung disease therapeutics is expected to grow significantly in the forthcoming years, driven by factors such as increasing rates of lung diseases, an aging population, and advances in medical technology.

Market Outlook

• Industry Growth Overview: The market continues to grow as the use of advanced biologic and targeted therapies increases and respiratory disease prevalence continues to be high.
• Sustainability Trends: The entire industry focuses on the development of 'green' inhalers and better disease treatment to lower the environmental impact of healthcare in the long run.
• Global Expansion: The strong global expansion remains particularly prominent in Asia-Pacific and North America due to better access to healthcare.
• Major Investors: The most important investors are HHS, NIH, Orbimed, Canaan, and Hatteras Venture Partners.

Market Scope

Market Dynamics

Driver

Rise in the prevalence of lung cancer

According to the American Cancer Society, it is estimated that around 238,340 current cases of lung cancer, 117,550 in men and 120,790 in women, and approximately 127,070 deaths from lung cancer, 67,160 in men and 59,910 in women are detected for lung cancer in the US 2023.

The rise in the prevalence of lung cancer is probably to have a significant impact on the lung disease therapeutics market. Advances in medical research and technology have led to the development of new and innovative therapies for lung diseases. These therapies may include targeted therapies, immunotherapies, and other novel approaches that may be more effective than traditional treatments. The growing focus on personalized medicine is driving the lung disease therapeutics market. Technological advancements in genetic testing and biomarker identification enable doctors to identify specific patient populations more appropriately to aid from certain therapies.

Restraint

High cost of research and development

The cost associated with research and development can be a primary barrier for industries. Creating a new drug from inception to approval can take over a decade and cost billions of dollars. This cost is mainly due to the complex and lengthy process of discovering and developing a new drug, which involves extensive research, clinical trials, and regulatory approvals. Lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary fibrosis are often chronic and progressive, making it challenging to develop effective treatments. The lungs are a complex organ system; developing drugs that can effectively target specific cells or tissues can be tricky. Despite these challenges, significant progress has been made in developing new lung disease therapeutics in recent years.

Opportunities

Advances in technology and medicine

Technological advances have allowed for identifying specific genetic mutations and proteins that play a role in lung diseases, leading to the development of targeted therapies to treat specific types of lung cancer or pulmonary diseases with greater precision and effectiveness. The advancement in drug delivery systems has allowed for more targeted and efficient delivery of medications to the lungs. Inhalation devices, for example, can deliver drugs directly to the disease site by minimizing the side effects and upgrading therapeutic outcomes. During the COVID-19 pandemic, telemedicine has immensely expanded and has the potential to improve access to lung care and increase patient engagement. Remote monitoring devices and virtual consultations can help patients manage their lung conditions more efficiently, enabling healthcare providers to deliver care more accurately.

Disease Type Insights

Asthma is the most prominent disease to raise the lung disease therapeutics market during the analyzed period. The rise in the lung disease therapeutics market can be attributed to an increasing prevalence of asthma and other lung diseases, growing awareness and diagnosis of the conditions, and advancements in medical technology and treatments. It includes the development of new and innovative drugs, increasing investment in research and development, and rising healthcare expenditure in emerging markets. Furthermore, the growing demand for personalized medicine and targeted therapies for asthma is expected to boost the growth of the asthma segment.

Drug Class Insights

The corticosteroids segment is expected to be the dominant drug class segment during the predicted period. Corticosteroids are a class of medications that have anti-inflammatory and immunosuppressive properties and are mainly used to treat lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). The corticosteroids market has the highest revenue and is currently generated by the segment of respiratory infections, which includes lung diseases such as asthma, COPD, and ILD due to the high prevalence of respiratory diseases worldwide and the widespread use of corticosteroids in their treatment. Therefore, corticosteroids are widely used in treating respiratory diseases, including lung diseases, and generate the highest revenue in the market.

A bronchodilator is expected to be the most lucrative segment throughout the forecast period

The bronchodilator and lung disease therapeutics market is expected to grow significantly in the coming years, driven by the rising prevalence of respiratory diseases, a growing geriatric population, and rising levels of air pollution. These are medications that relax the airways' muscles, making breathing easier. At the same time, lung disease therapeutics refer to drugs used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The COVID-19 pandemic has significantly impacted the bronchodilator and lung disease therapeutics market by contributing to an increase in respiratory illnesses and increasing demand for bronchodilators and lung disease therapeutics.

Molecule Type Insights

Biologics is expected to be the dominating molecule type segment during the predicted period

The contributing factors for the biologics market for lung disease therapeutics include asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), the growing geriatric population, and advancements in biologic drug development technologies. Even the increasing focus of biopharmaceutical companies on developing novel biologics for the treatment of lung diseases is expected to fuel the market's expansion. For instance, the development of monoclonal antibodies and other biologics that target specific molecules and pathways involved in the pathogenesis of lung diseases is expected to drive market growth. Furthermore, the growing trend of combination therapy, wherein two or more biologics are used together to treat lung diseases, is expected to further propel the growth of the lung disease therapeutics market.

The small molecules segment shows noticeable growth in the lung disease therapeutics market during the predicted period. There is a growing interest in developing small-molecule drugs for treating various lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis. Small molecules are organic compounds with low molecular weight, which allows them to easily penetrate cell membranes and interact with intracellular targets. These are designed to target specific molecular pathways involved in the development and progression of lung diseases, which can provide more targeted and effective treatments than traditional therapies. Moreover, small molecules often have better oral bioavailability and are easier to formulate into pill form, which can increase patient compliance and convenience.

Treatment Type Insights

Targeted therapy is the promising treatment type used in the lung disease therapeutics market during the forecast period. Targeted therapy has emerged as a promising approach for treating various lung diseases, including lung cancer and chronic obstructive pulmonary disease (COPD), where their process involves identifying and targeting specific molecules or pathways involved in the disease's development or progression, targeting to achieve better treatment outcomes and fewer side effects. Some other treatment options are bronchodilators, corticosteroids, and immunosuppressants, which dominate the therapeutics market for lung diseases. The market is highly competitive, with several key players competing to capture a larger market share.

Immunotherapy is expected to grow in the lung disease therapeutics market during the predicted period. Immunotherapy and lung disease therapeutics are both expanding markets, and the combination is predicted to be especially attractive for investors. It involves using a patient's immune system to fight cancer or other diseases. In contrast, the therapies aim to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Both markets have been growing in recent years due to the prevalence of these diseases and a growing awareness of the potential benefits of these treatments. For instance, lung cancer is an apparent cause of mortality in patients with COPD, and immunotherapy effectively treats lung cancer.

Distribution Channel Insights

Hospitals are the dominating lung disease therapeutic market. A few key players in the pharmaceutical industry dominated the hospital segment for lung disease by using therapies, including inhaled corticosteroids, bronchodilators, immune suppressants, and targeted therapies. In recent years, the demand for lung disease therapies has become increasingly competitive, with several fresh entrants. Some emerging players in this space include Vertex Pharmaceuticals, which holds a significant market share due to its established brands and extensive R&D pipelines. As new therapies continue, the competitive landscape of the hospital segment for lung disease will likely evolve.

Online shows lucrative growth in the lung disease therapeutics market. The online therapeutic market for lung diseases became focused due to Covid -19 pandemic, and the demand has risen for numerous reasons. According to the World Health Organization (WHO), lung diseases are responsible for approximately 3 million deaths worldwide yearly. The prevalence of Covid-19 in recent years along with multiple restrictions implemented across the globe boosted the growth of the online segment.

The growth of online segment for lung disease therapeutics is attributed to the rising number of home care settings, especially for geriatric population, more convenience offered by online medicine shopping and available options for door-step delivery.

Regional Insights

U.S. Lung Disease Therapeutics Market Size and Growth 2026 to 2035

The U.S. lung disease therapeutics market size is accounted at USD 24.40 billion in 2025 and predicted to increase from USD 25.87 billion in 2026 to approximately USD 45.46 billion by 2035, representing a CAGR of 6.42% from 2026 to 2035.

North America is the dominating lung disease therapeutic market throughout the projection period.The United States is North America's largest lung disease therapeutics market regarding regional dominance accounting for a significant market share. This is due to the country's high prevalence of lung diseases, the availability of advanced healthcare infrastructure, and technological advancements in treatment options. Canada is also a significant market for lung disease therapeutics, owing to the country's rising prevalence of respiratory diseases.

Asia-Pacific is the fastest-growing lung disease therapeutics market during the forecast period. The region is home to some of the world's largest populations, particularly India, China, and is experiencing a rise in chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. These diseases significantly burden healthcare systems in the region, driving demand for innovative and effective treatments, the increasing prevalence of lung cancer, rising healthcare expenditure, and a growing focus on early diagnosis and treatment.

U.S. Lung Disease Therapeutics Market Trends:

The market in the U.S. profits from the quick acceptance of targeted therapies and immunotherapies. The strong integration of digital health tools facilitates remote monitoring for asthma and chronic respiratory diseases, while the advanced clinical research ecosystems speed up the creation of personalized care pathways, the transition of therapeutic discoveries into clinical practice, and the innovation process.

What Are the Driving Factors of The Lung Disease Therapeutics Market in Europe?

Europe is a developed market where strong public healthcare systems and standardized treatment protocols play an important supporting role. The focus on early detection, patient education, and long-term disease management is the main reason for the adoption of the technology. The increasing number of elderly patients and the existence of coordinated respiratory care programs are the factors that keep the demand for advanced therapeutics coming across a variety of lung disease indications.

Germany Lung Disease Therapeutics Market Trends:

The market in Germany has been influenced by the need for occupational health, the existence of structured screening programs that are structured, and the use of evidence-based treatment approaches. The public healthcare sector is concerned with the effectiveness of long-term therapy. The funding of AI-supported diagnostics and imaging is aimed at earlier intervention, accurate subtyping of diseases, and improved outcomes for chronic respiratory patients.

Asia Pacific: China Lung Disease Therapeutics Market Trends:

China holds great potential because of the high lung disease incidence rate and the improvement of urban healthcare infrastructure. The government-supported innovation programs are a great ally in the promotion of domestic drug development. People are becoming more aware, the diagnostics are getting better, and the various treatment modalities, including advanced therapeutics, are all working hand in hand to rapidly increase the treatment capabilities for lung diseases across the country.

Lung Disease Therapeutics Market-Value Chain Analysis

• R&D: Potential drug target identification and preclinical research to find new innovative compounds for various lung diseases.
  Key players: Pfizer, AstraZeneca, Roche
• Clinical Trials and Regulatory Approvals: Human testing carried out under strict conditions to prove safety and efficacy, and to get the approvals from the regulatory authorities for the treatments.
  Key Players: IQVIA, ICON plc, Parexel
• Formulation and Final Dosage Preparation: Mixing the active ingredients with other substances to produce the stable, safe, and patient-ready dosage forms.
  Key players: Catalent, Lonza, Thermo Fisher Scientific
• Packaging and Serialization: Ensuring the product integrity while allowing the traceability, compliance with regulations, and prevention of counterfeiting across the markets.
  Key players: West Pharmaceutical Services, Schott AG, Gerresheimer
• Distribution to Hospitals, Pharmacies of Lung Disease Therapeutics: Taking care of the logistics in a very secure manner so that the therapies are available for use in patient care without delay.
  Key players: McKesson Corporation, Cardinal Health, AmerisourceBergen

Top Companies in the Lung Disease Therapeutics Market & Their Offerings:

• Johnson & Johnson: Their main aim is lung cancer therapeutics, and they are providing targeted oncology treatments to patients with complex, genetically mutation-driven respiratory malignancies.
• Amgen Inc.: They are working on the development of new oncology and respiratory medicines, which include lung cancer and severe asthma treatment.
• AstraZeneca: The company has the most effective drugs for lung cancer management, and the targeted and immunotherapy treatments are mature for all disease stages.

Lung Disease Therapeutics MarketCompanies

• Johnson & Johnson
• Amgen Inc.
• AstraZeneca
• Boehringer Ingelheim
• Pfizer Inc.
• Allergan Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche
• Merck & Co
• Teva Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• Novartis AG

Segments Covered in the Report

By Disease Type

• Asthma
• Lung Cancer
• Chronic Obstructive Pulmonary Disease (COPD)

By Drug Class

• Corticosteroids
• Bronchodilator
• Antimicrobial
• Alkylating Agents
• Mucolytics

By Molecule Type

• Small molecules
• Biologics

By Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

By Distribution Channel

• Online
• Hospital
• Retail

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa